A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
An 18-year-old with Norwood 2 hair loss is considering finasteride treatment. Bloodwork shows testosterone and hormone levels mostly within normal ranges, except for low estradiol.
The user experienced significant hair regrowth using Trestolone, GHK-Cu, and Minoxidil. They avoided Finasteride due to concerns about side effects and noted that their approach reduced androgenic load, contributing to hair regrowth.
The conversation discusses hair thinning potentially linked to gut health issues and suggests biotin as a possible treatment. It also mentions that hair thinning could be due to male pattern baldness (MPB).
The conversation discusses using a TCA 35% chemical peel on the scalp to potentially improve hair growth by addressing fibrosis and enhancing the effectiveness of topical treatments. The user also mentions trying microneedling and other methods like topical metformin and dutasteride for hair regrowth.
Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.
The conversation discusses hair loss and the impact of testosterone and DHT levels, with suggestions to monitor these levels and consider vitamin D supplementation. Treatments mentioned include finasteride and possibly minoxidil.
Finasteride has no effect on the user's estradiol levels, and body fat may influence aromatization. The user is on testosterone replacement therapy and uses everyday injections to manage high RBC count, with plans to measure DHT, DHEA-S, and pregnenolone levels.
Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.
OP underwent a hair transplant (HT) and has been using finasteride for one year. Despite having thin hair, OP is happy with the results and feels more confident.
A user gained 10-12 kg after starting finasteride but found their estrogen levels to be within the normal range. They are concerned about potential gynecomastia but are reassured by their lab results.
A poor diet high in sugar and insulin resistance may reduce the effectiveness of finasteride in treating hair loss. Improving diet could potentially enhance treatment results.
Hair loss discussion mentions treatments like Finasteride, Dutasteride, and Minoxidil. Users share experiences, side effects, and advice on using these treatments.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A 21-year-old is considering a hair transplant in Turkey due to aggressive hair loss and scalp psoriasis, but is advised to try finasteride and minoxidil for at least a year to stabilize hair loss before proceeding. The user is concerned about side effects but plans to consult a dermatologist and possibly start finasteride.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.
Treatments for hair loss with a focus on finasteride, minoxidil, and platelet-rich plasma (PRP). The user discussed their family history of balding, asked questions about the effectiveness of different treatments, and was discouraged from taking finasteride by medical professionals.
A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.
The conversation discusses using topical finasteride for hair loss, with concerns about its safety around family members, especially pregnant women and infants. One user plans to try topical finasteride due to side effects from the pill.
The user is experiencing low libido and mood swings after starting a low dose of topical finasteride. They are considering further blood tests to investigate low testosterone levels and other hormonal factors.
The user experienced genital itching while using finasteride and noticed a yellow bump, which improved with clotrimazole, but the itching persists. The discussion focuses on side effects of finasteride.
A 29-year-old male experiencing hair loss due to TRT is using minoxidil and dermarolling but is hesitant to use finasteride or dutasteride due to potential side effects. He is considering low level laser therapy (LLLT), PRP, ketoconazole shampoo, and oral minoxidil as additional treatments. A reply suggests that without a DHT blocker like finasteride or dutasteride, other treatments may not be effective long-term.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.